A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors
ConditionAdvanced/Metastatic Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorAntengene Biologics Limited
About this trial
This is an Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients with Advanced/metastatic Solid Tumors
Eligibility criteria
Qualifiers
Provision of signed and dated, written informed consent prior to any study-specific procedures, sampling, and analyses.
Aged at least 18 years as of the date of consent.
Histological or cytological confirmation of a solid tumor, and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or not applicable for standard therapy(ies).
Dose Escalation Phase: all solid tumors.
Disqualifiers
Primary central nervous system disease or central nervous system metastatic disease.
Prior exposure to a Claudin 18.2 targeting agent.
Prior therapy with any chemotherapy, immunotherapy, anticancer agents, or investigational products from a previous clinical study within 28 days of the first dose of study treatment or within a period during which the investigational product or systemic anticancer treatment has not been cleared from the body (eg, a period of 5 'half-lives'.
Prior vaccination within 28 days of the first dose of study therapy.
Trial design
Treatments tested in this trial
- ATG-022
Treatment groups
156 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov